Bioxcel therapeutics provides an update on its ongoing phase 3 serenity trials

Bioxcel therapeutics provides an update on its ongoing phase 3 serenity trials.bioxcel therapeutics - currently maintains previous guidance that serenity i & ii are expected to be completed by mid-year 2020.bioxcel therapeutics - has not observed change in enrollment rates resulting from covid-19 pandemic.bioxcel therapeutics - on track to report topline data from both studies in mid-2020.
BTAI Ratings Summary
BTAI Quant Ranking